Skip to main content

Table 5 Univariate and multivariate competing risk regression analyses of Grade 2 or higher radiation necrosis (RN) (n = 156)

From: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

 

Univariate analysis

Multivariate analysis

 

HR (95% CI)

p Value

HR (95% CI)

p Value

Number of BMs

Group A

2.10 (0.67–6.60)

0.200

1.72 (0.53–5.60)

0.370

Group B

Ref

Ref

Group C

1.21 (0.22–6.52)

0.820

1.13 (0.18–7.15)

0.900

Age (years)

 < 65

Ref

Ref

 ≥ 65

0.81 (0.28–2.35)

0.700

0.79 (0.24–2.57)

0.690

Gender

Female

Ref

Ref

Male

1.13 (0.42–2.98)

0.810

0.91 (0.32–2.59)

0.870

Primary site

Lung

Ref

Ref

GI

0.44 (0.06–3.44)

0.430

0.57 (0.07–4.91)

0.610

Breast

N.A

N.A

N.A

N.A

Others

0.50 (0.11–2.16)

0.350

0.53 (0.11–2.61)

0.440

KPS

 ≥ 80

Ref

Ref

 ≤ 70

0.48 (0.16–1.48)

0.200

0.52 (0.12–2.21)

0.370

Extracranial lesions

Controlled

Ref

Ref

Uncontrolled

0.33 (0.12–0.87)

0.025

0.44 (0.15–1.31)

0.140

fSRT or SRS

SRS

Ref

Ref

fSRT

1.34 (0.51–3.54)

0.560

1.35 (0.35–5.16)

0.670

Total PTV volume (cm3)

1 (≥ 15)

1.10 (0.27–4.59)

0.890

1.57 (0.24–10.33)

0.640

2 (≥ 4, < 15)

1.86 (0.61–5.64)

0.270

2.00 (0.51–

0.320

3 (< 4)

Ref

7.91)Ref

  1. RN Radiation necrosis, BMs Brain metastases, GI Gastrointestinal cancers, KPS Karnofsky performance status, fSRT Fractionated stereotactic radiotherapy, SRS Stereotactic radiosurgery, PTV Planning target volume